Hua M. Xiang

State Key Laboratory Of Natural Medicines And Department Of Medicinal Chemistry
Nanjing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer.

The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer.

Journal: Drug discovery today

Published: May 23, 2026

Discovery of an orally bioavailable selenium-containing Polθ inhibitor with a dual mechanism of DNA damage and immune activation for HR-deficient cancers.

Discovery of an orally bioavailable selenium-containing Polθ inhibitor with a dual mechanism of DNA damage and immune activation for HR-deficient cancers.

Journal: European journal of medicinal chemistry

Published: March 08, 2026

Isothiocyanate-mediated cyclization of phage-displayed peptides enables discovery of macrocyclic binders.

Isothiocyanate-mediated cyclization of phage-displayed peptides enables discovery of macrocyclic binders.

Journal: Science advances

Published: February 06, 2026

A patent review of DNA polymerase theta (Polθ) targeted therapies (2019-2025).

A patent review of DNA polymerase theta (Polθ) targeted therapies (2019-2025).

Journal: Expert opinion on therapeutic patents

Published: January 10, 2026

Approved Steroidal Drugs (2000-2025): A Medicinal Chemistry Perspective.

Approved Steroidal Drugs (2000-2025): A Medicinal Chemistry Perspective.

Journal: Journal of medicinal chemistry

Published: January 06, 2026

Reactive formation of magnesiowüstite at the lunar core-mantle boundary.

Reactive formation of magnesiowüstite at the lunar core-mantle boundary.

Journal: Nature communications

Published: December 19, 2025

Targeted degradation of Werner syndrome helicase (WRN) via ligand-directed covalent hydrophobic tagging.

Targeted degradation of Werner syndrome helicase (WRN) via ligand-directed covalent hydrophobic tagging.

Journal: European journal of medicinal chemistry

Published: June 08, 2025

Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model.

Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model.

Journal: Journal of medicinal chemistry

Published: March 21, 2025

Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial.

Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial.

Journal: Journal of medicinal chemistry

Published: October 09, 2024

Discovery of a highly potent, N-terminal domain-targeting degrader of AR-FL/AR-V7 for the treatment of prostate cancer.

Discovery of a highly potent, N-terminal domain-targeting degrader of AR-FL/AR-V7 for the treatment of prostate cancer.

Journal: European journal of medicinal chemistry

Published: September 05, 2024

Structure-Activity Relationship (SAR) Studies of Novel Monovalent AR/AR-V7 Dual Degraders with Potent Efficacy against Advanced Prostate Cancer.

Structure-Activity Relationship (SAR) Studies of Novel Monovalent AR/AR-V7 Dual Degraders with Potent Efficacy against Advanced Prostate Cancer.

Journal: Journal of medicinal chemistry

Published: March 21, 2024

Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors.

Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors.

Journal: Journal of medicinal chemistry

Published: February 20, 2024

Showing 1-12 of 82

Last Updated: 09/26/2026